- Home
- MXCT vs SGMT Comparison
MXCT vs SGMT Comparison
Compare MXCT & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MXCT
- SGMT
- Stock Information
- Founded
- MXCT 1999
- SGMT 2006
- Country
- MXCT United States
- SGMT United States
- Employees
- MXCT N/A
- SGMT N/A
- Industry
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- SGMT
- Sector
- MXCT Health Care
- SGMT
- Exchange
- MXCT Nasdaq
- SGMT Nasdaq
- Market Cap
- MXCT 242.4M
- SGMT 269.2M
- IPO Year
- MXCT 2021
- SGMT 2023
- Fundamental
- Price
- MXCT $2.04
- SGMT $8.25
- Analyst Decision
- MXCT Strong Buy
- SGMT Strong Buy
- Analyst Count
- MXCT 2
- SGMT 6
- Target Price
- MXCT $7.50
- SGMT $26.83
- AVG Volume (30 Days)
- MXCT 473.0K
- SGMT 825.5K
- Earning Date
- MXCT 08-06-2025
- SGMT 08-13-2025
- Dividend Yield
- MXCT N/A
- SGMT N/A
- EPS Growth
- MXCT N/A
- SGMT N/A
- EPS
- MXCT N/A
- SGMT N/A
- Revenue
- MXCT $37,675,000.00
- SGMT N/A
- Revenue This Year
- MXCT $8.36
- SGMT N/A
- Revenue Next Year
- MXCT $20.14
- SGMT N/A
- P/E Ratio
- MXCT N/A
- SGMT N/A
- Revenue Growth
- MXCT N/A
- SGMT N/A
- 52 Week Low
- MXCT $1.97
- SGMT $1.73
- 52 Week High
- MXCT $5.20
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- MXCT 40.39
- SGMT 44.47
- Support Level
- MXCT $2.18
- SGMT $8.79
- Resistance Level
- MXCT $2.31
- SGMT $11.41
- Average True Range (ATR)
- MXCT 0.11
- SGMT 0.84
- MACD
- MXCT -0.01
- SGMT -0.28
- Stochastic Oscillator
- MXCT 18.52
- SGMT 7.60
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.